Search our Database of Scientific Publications and Authors

I’m looking for a

    2384 results match your criteria Cutaneous B-Cell Lymphoma

    1 OF 48

    MCL-1 is modulated in Crohn's disease fibrosis by miR-29b via IL-6 and IL-8.
    Cell Tissue Res 2017 Feb 11. Epub 2017 Feb 11.
    Centre for Genomics and Child Health and National Centre for Bowel Research, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, 4 Newark St, Whitechapel, E1 2AT, London, UK.
    The miR-29 family is involved in fibrosis in multiple organs, including the intestine where miR-29b facilitates TGF-β-mediated up-regulation of collagen in mucosal fibroblasts from Crohn's disease (CD) patients. Myeloid cell leukemia-1 (MCL-1), a member of the B-cell CLL/Lymphoma 2 (BCL-2) apoptosis family, is involved in liver fibrosis and is targeted by miR-29b via its 3'-UTR in cultured cell lines. We investigate the role of MCL-1 and miR-29b in primary intestinal fibroblasts and tissue from stricturing CD patients. Read More

    Intralesional anti-CD20 antibody for low-grade primary cutaneous B-cell lymphoma: Adverse reactions correlate with favorable clinical outcome.
    J Dtsch Dermatol Ges 2017 Feb 8. Epub 2017 Feb 8.
    Department of Dermatology, Eberhard Karls University, Tübingen, Germany.
    Background And Objectives: Intralesional injection of anti-CD20 antibody (rituximab) has been described as effective therapeutic option for patients with indolent primary cutaneous B-cell lymphoma (PCBL). To date, no parameters that reproducibly predict favorable clinical outcome of this treatment have been identified. The study aims to evaluate the clinical response and adverse effects as well as patients' self-perception of intralesional injection of anti-CD20 antibody for treatment of indolent PCBL compared to other treatment modalities. Read More

    Retrospective study of intravascular large B-cell lymphoma cases diagnosed in Quebec: A retrospective study of 29 case reports.
    Medicine (Baltimore) 2017 Feb;96(5):e5985
    aDepartment of Hematology-Oncology at Sherbrooke University Hospital Center, CIUSSS Estrie, University of Sherbrooke, Sherbrooke bDepartment of Pathology at Sherbrooke University Hospital Center, CIUSSS Estrie, University of Sherbrooke, Sherbrooke cDepartment of Hematology-Oncology at McGill University Health Centre, CIUSSS Centre-Ouest-de-l'Île-de-Montréal, McGill University, Montreal dDepartment of Pathology at Laval University Hospital Center, CIUSSS Capitale Nationale, University Laval, Quebec eDepartment of Hematology-Oncology at Chicoutimi Hospital, CIUSSS Saguenay-Lac-Saint-Jean, University of Sherbrooke, Chicoutimi fDepartment of Pathology at Montreal University Hospital Center, CIUSSS Est-de-l'Île-de-Montréal, University of Montreal, Montreal gDepartment of Pathology at Charles-Lemoyne Hospital, CIUSSS Montérégie-Centre, University of Sherbrooke, Longueuil hDepartment of Pathology at Cité-de-la-Santé Hospital, CIUSSS Laval, Laval iDepartment of Hematology-Oncology at Montreal University Hospital Center in Trois-Rivières, CIUSSS Mauricie-et-du-Centre-du-Québec, Trois-Rivieres jDepartment of Hematology-Oncology at Maisonneuve-Rosemont Hospital, CIUSSS Est-de-l'Île-de Montréal, University of Montreal, Montreal, Quebec, Canada.
    Introduction: Intravascular large B-cell lymphoma (IVL) is an extremely rare malignancy, mainly studied through European and Asian series. Due to the low incidence of this condition, our understanding of the clinical presentation as well as the management of IVL relies on a limited number of patients.We report the largest North American study to date on IVL with 29 cases from Quebec hospital diagnosed between 1990 and 2016. Read More

    IgG4 Expression in Primary Cutaneous Marginal Zone Lymphoma: A Multicenter Study.
    Appl Immunohistochem Mol Morphol 2017 Feb 1. Epub 2017 Feb 1.
    *Department of Dermatology ‡Harvard Medical School §Department of Pathology, Massachusetts General Hospital, Boston, MA †Kempf and Pfaltz, Histologische Diagnostik, Zürich, Switzerland ∥Dermatopathologie Friedrichshafen, Germany.
    Background: Primary cutaneous marginal zone lymphoma (PCMZL) is the second most common B-cell lymphoma of the skin. A recent study has demonstrated a strikingly high prevalence of immunoglobulin (Ig)G4 expression in PCMZL with plasmacytic differentiation.

    Objective: The objective was to investigate the incidence of IgG4 expression in PCMZL, and its correlation with clinical and immunophenotypic features. Read More

    B Cell Lymphoma Underlying Paraffinoma of Glabella.
    J Craniofac Surg 2017 Jan 30. Epub 2017 Jan 30.
    *Department of Plastic and Reconstructive Surgery †Department of Pathology, Haeundae Paik Hospital, College of Medicine, The Inje University, Busan, Republic of Korea.
    Soft tissue reactions to paraffin include inflammation, fibrosis, disfigurement, and granulomatous inflammation with foreign body giant cell reaction. The authors report the case of a 77-year-old woman with cutaneous marginal zone B cell lymphoma located on glabella, arising in association with underlying paraffinoma. While it is unclear whether the implant directly contributed to the development of lymphoma, this association has not been previously documented, prompting this report. Read More

    Primary Cutaneous Follicular Helper T-cell Lymphoma in a Patient With Neurofibromatosis Type 1: Case Report and Review of the Literature.
    Am J Dermatopathol 2017 Feb;39(2):134-139
    *Sunnybrook Health Science Centre, Division of Dermatology, University of Toronto, Toronto, Ontario; and †University Health Network, Toronto General Hospital, University of Toronto, Department of Pathology, Toronto, Ontario.
    Patients with neurofibromatosis type 1 (NF-1) have a well-known predisposition for certain types of malignancies, including lymphoproliferative disorders. Cutaneous T-cell lymphoma (CTCL) has been reported in patients with NF-1, although it is considered a rare entity in this subset of patients. Cutaneous follicular helper T-cell lymphoma (CTFHCL) is a recently emerged rare subtype of CTCL with peculiar clinical and histopathological features and represents a diagnostic and therapeutic challenge. Read More

    Primary cutaneous diffuse large B-cell lymphoma presenting as chronic non-healing ulcer.
    Int Wound J 2017 Jan 24. Epub 2017 Jan 24.
    Department of Dermatology and Cutaneous Surgery, University of Miami School of Medicine, Miami, FL, USA.
    Primary cutaneous diffuse large B-cell lymphoma is an uncommon and aggressive lymphoproliferative disorder with a rapid growth rate and dismal prognosis. We present the case of a 91-year-old female with an unusual manifestation of primary cutaneous diffuse large B-cell lymphoma, mimicking other more prevalent diseases like chronic non-healing venous ulceration. Dermatopathologic evaluation rendered the correct diagnosis. Read More

    Evolving prevalence of haematological malignancies in orphan designation procedures in the European Union.
    Orphanet J Rare Dis 2017 Jan 21;12(1):17. Epub 2017 Jan 21.
    Universidade de Lisboa, Faculdade de Farmácia, Avenida Professor Gama Pinto, 1649-003, Lisboa, Portugal.
    The Committee for Orphan Medicinal Products (COMP) evaluates prevalence of rare conditions as one of the criteria for granting an orphan designation with a prevalence threshold of 5 in 10.000. At the time of Marketing Authorisation (MA) these criteria are reassessed to ensure they are still met. Read More

    A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma.
    Leuk Lymphoma 2017 Jan 19:1-9. Epub 2017 Jan 19.
    a Massey Cancer Center, Virginia Commonwealth University , Richmond , VA , USA.
    A phase 1 study was conducted to determine the dose-limiting toxicities and maximum-tolerated dose (MTD) for bortezomib followed by romidepsin on days 1, 8, and 15 in patients with relapsed/refractory CLL/SLL or B- or T-cell lymphoma. Eighteen treated patients were evaluable for response. The MTD was 1. Read More

    Primary cutaneous B-cell lymphomas with large cell predominance-primary cutaneous follicle center lymphoma, diffuse large B-cell lymphoma, leg type and intravascular large B-cell lymphoma.
    Semin Diagn Pathol 2016 Dec 2. Epub 2016 Dec 2.
    Department of Pathology, University of California San Francisco, USA; Department of Dermatology, University of California San Francisco, USA. Electronic address:
    In this review, we present clinical features and detailed histopathologic, immunologic, and molecular information regarding primary cutaneous follicle center lymphoma and primary cutaneous diffuse large B-cell lymphoma, leg type which together represent two of the three most common types of primary cutaneous B-cell lymphoma recognized in the current WHO classification system.(1,2) Overall, B-cell lymphomas represent 19-27% of primary cutaneous lymphomas in most large European and American studies(3-6) and together, primary cutaneous follicle center lymphoma and primary cutaneous diffuse large B-cell lymphoma, leg type account for approximately 2/3 to ¾ of these cases.(5,7-11) Both subtypes can contain a high content of large B-lymphocytes, although most cases of primary cutaneous follicle center lymphomas exhibit a range in cell size and cytology. Read More

    A new era for cutaneous CD30-positive T-cell lymphoproliferative disorders.
    Semin Diagn Pathol 2016 Nov 29. Epub 2016 Nov 29.
    Kempf und Pfaltz, Histologische Diagnostik, Zürich, Switzerland; Department of Dermatology, University Hospital Zurich, CH-8091, Zurich, Switzerland. Electronic address:
    Cutaneous CD30+ T-cell lymphoproliferative disorders (CD30+ T-LPD) represent a spectrum encompassing lymphomatoid papulosis (LyP), primary cutaneous anaplastic large-cell lymphoma (pcALCL) and borderline lesions. They share the expression of CD30 as a common phenotypic marker. They differ however in their clinical presentation, the histological features and clinical course. Read More

    Cutaneous B-cell lymphomas - pathogenesis, diagnostic workup, and therapy.
    J Dtsch Dermatol Ges 2016 Dec;14(12):1207-1224
    Department of Dermatology, Venereology, and Allergology, University Hospital Würzburg, Germany.
    Cutaneous B-cell lymphomas (CBCLs) comprise a group of mature lymphoproliferative B-cell disorders that primarily affect the skin. Characterized by great biological and clinical variability among its various subtypes, CBCLs fundamentally differ from primary nodal or systemic B-cell lymphomas. Given their uncomplicated course and excellent prognosis, lymphoma classifications rank primary cutaneous marginal zone lymphoma (PCMZL) and primary cutaneous follicle center lymphoma (PCFCL) as indolent CBCLs. Read More

    Cutaneous EBV-related lymphoproliferative disorders.
    Semin Diagn Pathol 2016 Dec 7. Epub 2016 Dec 7.
    Hematopathology, National Cancer Institute (NCI), Bethesda, MD, USA.
    This article will focus on the cutaneous lymphoproliferative disorders associated with EBV, with an emphasis on the upcoming changes in the revised 4th Edition of the WHO classification of tumors of the hematopoietic system, many of which deal with cutaneous disorders derived from NK-cells or T-cells. Extranodal NK/T-cell lymphoma usually presents in the upper aerodigestive tract, but can involve the skin secondarily. EBV-associated T- and NK-cell lymphoproliferative disorders (LPD) in the pediatric age group include the systemic diseases, chronic active EBV infection (CAEBV) and systemic EBV+ T-cell lymphoma of childhood. Read More

    Cutaneous marginal zone lymphomas.
    Semin Diagn Pathol 2016 Nov 29. Epub 2016 Nov 29.
    Division of Hematopathology, Department of Pathology, University of Pittsburgh School of Medicine, UPMC-Presbyterian, G-335, 200 Lothrop Street, Pittsburgh, PA 15213. Electronic address:
    Primary cutaneous marginal zone lymphoma (CMZL) is one of the major primary B-cell lymphomas of skin. Two types are recognized: a more common class-chain switched CMZL, and a much less common IgM+ CMZL. The extremely indolent course, together with other features distinct from most other MALT lymphomas, has led some to question whether at least the class-switched cases should be considered an overt lymphoma. Read More

    Past, present and future of cutaneous lymphomas.
    Semin Diagn Pathol 2016 Nov 28. Epub 2016 Nov 28.
    Research Unit Dermatopathology, Department of Dermatology, Medical University of Graz, Auenbruggerplatz 8, 8036 Graz, Austria. Electronic address:
    Primary cutaneous lymphomas represent a broad group of diseases with different clinical, histopathological, phenotypic, molecular, and prognostic features. All cutaneous lymphomas share the same tropism of neoplastic lymphocytes for the skin, but precise classification is paramount for proper management of the patients. Primary cutaneous lymphomas are classified according to the schemes proposed by the European Organization for Research and Treatment of Cancer (EORTC)-Cutaneous Lymphomas Task Force together with the World Health Organization (WHO) in 2005, and the WHO classification of 2008 with the 2016 update. Read More

    Diagnostic, prognostic and therapeutic role of CD30 in lymphoma.
    Expert Rev Hematol 2017 Jan 21;10(1):29-37. Epub 2016 Dec 21.
    a Hematology & Oncology , University of Alabama at Birmingham , Birmingham , AL , USA.
    Introduction: CD30 is a cell surface receptor expressed in classical Hodgkin lymphoma (HL), anaplastic large cell lymphoma (ALCL), and many other lymphomas to a variable degree. It has been identified as an important therapeutic target in lymphoma. Areas covered: CD30 testing is essential in diagnosis of classical HL and ALCL, and expression can also be seen in other lymphoma subtypes. Read More

    A Clinicopathological Analysis of Primary Cutaneous Lymphomas: A 6-year Observational Study at a Tertiary Care Center of South India.
    Indian J Dermatol 2016 Nov-Dec;61(6):608-617
    Department of Pathology, Government Medical College, Kozhikode, Kerala, India.
    Background: Little data are available concerning clinical and pathological patterns of cutaneous lymphomas in India.

    Aim: To analyze the clinical and histopathological characteristics of cutaneous lymphomas in Indian patients.

    Materials And Methods: This is a single-center, prospective, observational study carried out from January 1, 2010, to December 31, 2015. Read More

    Lymphoma of the eyelid.
    Surv Ophthalmol 2016 Nov 26. Epub 2016 Nov 26.
    Department of Pathology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; Department of Ophthalmology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. Electronic address:
    Lymphoma of the eyelid constitutes 5% of ocular adnexal lymphoma. In previously published cases, 56% of lymphomas of the eyelid are of B-cell origin and 44% are of T-cell origin. The most frequent B-cell lymphomas are extranodal marginal zone lymphoma (27 cases-14%) and diffuse large B-cell lymphoma (18 cases-9%). Read More

    Histone deacetylase inhibitors interrupt HSP90•RASGRP1 and HSP90•CRAF interactions to upregulate BIM and circumvent drug resistance in lymphoma cells.
    Leukemia 2016 Dec 16. Epub 2016 Dec 16.
    Division of Oncology Research, Department of Oncology, Mayo Clinic College of Medicine, Rochester, MN, USA.
    Histone deacetylase (HDAC) inhibitors, which are approved for the treatment of cutaneous T-cell lymphoma and multiple myeloma, are undergoing evaluation in other lymphoid neoplasms. How they kill susceptible cells is incompletely understood. Here, we show that trichostatin A, romidepsin and panobinostat induce apoptosis across a panel of malignant B cell lines, including lines that are intrinsically resistant to bortezomib, etoposide, cytarabine and BH3 mimetics. Read More

    MYD88 mutations in a distinct type of cutaneous marginal zone lymphoma with a non-class switched IgM-immunophenotype.
    Br J Dermatol 2016 Nov 18. Epub 2016 Nov 18.
    Institute of Pathology, Comprehensive Cancer Center, University of Wuerzburg, Germany.
    Somatic mutations in the MYD88 gene are involved in the molecular pathogenesis of different subtypes of Non-Hodgkin B-cell lymphomas such as diffuse large B-cell lymphoma, lymphoplasmacytic lymphoma and Waldenstrom's macroglobulinemia(1) . Albeit with much lower frequency, the key driver mutation MYD88 (c.794T>C, p. Read More

    Proteomic Approaches to Biomarker Discovery in Cutaneous T-Cell Lymphoma.
    Dis Markers 2016 16;2016:9602472. Epub 2016 Oct 16.
    Dermatology Research Laboratory, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania; Department of Dermatology, Carol Medical Center, 020915 Bucharest, Romania.
    Cutaneous T-cell lymphoma (CTCL) is the most frequently encountered type of skin lymphoma in humans. CTCL encompasses multiple variants, but the most common types are mycosis fungoides (MF) and Sezary syndrome (SS). While most cases of MF run a mild course over a period of many years, other subtypes of CTCL are very aggressive. Read More

    Pattern of skin cancer among Saudi patients attending a tertiary care center in Dhahran, Eastern Province of Saudi Arabia. A 20-year retrospective study.
    Int J Dermatol 2016 Dec 3;55(12):1396-1401. Epub 2016 Jun 3.
    Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia.
    Skin cancer is the ninth most common malignancy in Saudi Arabia. It represented 3.2% of all newly diagnosed cancer cases in the year 2010. Read More

    Occurrence of lymphoma in non-gonadal organ during pregnancy: a report on four cases and literature review.
    Cancer Biol Med 2016 Sep;13(3):399-403
    Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China.
    Lymphoma rarely occurs during pregnancy, making this condition difficult to define. Lymphomas that occur in reproductive organs during pregnancy exhibit unique clinical characteristics. Among the limited cases, non-Hodgkin's lymphoma (NHL) shows a considerably higher incidence rate than Hodgkin's lymphoma (HL); NHL also displays clinical characteristics, such as high aggressiveness, advanced stage, and poor outcome. Read More

    De Novo CD5-Positive Diffuse Large B-Cell Lymphoma: Report of a Case Presenting With Cutaneous Involvement and Featuring Extensive Intravascular Dissemination on Postmortem Examination.
    Int J Surg Pathol 2016 Dec 17;24(8):763-768. Epub 2016 Jul 17.
    Department of Pathology, Hospital Universitario Fundación Jiménez Díaz, Madrid.
    De novo CD5-positive diffuse large B-cell lymphoma (DLBCL) represents 10% of DLBCLs and is frequently associated with an aggressive clinical course and poor response to chemotherapy. We report a case of an 84-year old man who presented with cutaneous lesions, malaise, and B-symptoms. A skin biopsy revealed neoplastic cells within the lumen of dermal vessels. Read More

    The role of 18F-FDG PET and PET/CT in the evaluation of primary cutaneous lymphoma.
    Nucl Med Commun 2017 Feb;38(2):106-116
    Departments of aNuclear Medicine bRadiology, Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan, People's Republic of China.
    Primary cutaneous lymphoma (PCL) is the second most common type of extranodal non-Hodgkin lymphoma, including both cutaneous T-cell and B-cell lymphomas. PCL comprises numerous subtypes and thus has myriad clinical presentations in the skin and subcutaneous tissues. Accurate classification and staging are important for making treatment recommendations for PCL and will further impact patient prognosis significantly. Read More

    Primary cutaneous B-cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: Comparison with current classification and definition of prognostic markers.
    Cancer Med 2016 Oct 26;5(10):2740-2755. Epub 2016 Sep 26.
    Unit of Anatomic Pathology, Department of Molecular Medicine, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
    Categorization of primary cutaneous B-cell lymphomas (PCBCL) other than marginal zone (MZL) represents a diagnostic challenge with relevant prognostic implications. The 2008 WHO lymphoma classification recognizes only primary cutaneous follicular center cell lymphoma (PCFCCL) and primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT), whereas the previous 2005 WHO/EORTC classification also included an intermediate form, namely PCDLBCL, other. We conducted a retrospective, multicentric, consensus-based revision of the clinicopathologic characteristics of 161 cases of PCBCL other than MZL. Read More

    A case report of mantle cell lymphoma manifesting as a foot lesion.
    Tumori 2016 Nov 11;102(Suppl. 2). Epub 2016 Nov 11.
    Wakefield Clinical Laboratories, Department of Pathology, Montefiore Medical Center, Bronx, New York - USA.
    Introduction: Mantle cell lymphoma (MCL) is a rare B-cell non-Hodgkin lymphoma that most commonly affects men above the age of 60 years. The disease is called MCL because the tumor cells originate from the mantle zone of the lymph node. The most commonly affected sites are the lymph nodes, bone marrow, gastrointestinal tract, Waldeyer's ring and rarely the skin, breast and central nervous system. Read More

    Pegylated liposomal-encapsulated doxorubicin in cutaneous composite lymphoma: A case report.
    Medicine (Baltimore) 2016 Oct;95(43):e4796
    Department of Dermatology and Allergology, Insitute of Pathology "Georg Schmorl", Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany.
    Background: Cutaneous composite lymphomas are very rare. Their treatment depends upon the different contributing lymphoma entities. Peripheral T-cell lymphoma, not otherwise specified, (PTCL-NOS) represents an aggressive lymphoma subtype. Read More

    Cyclin D1 expression in peripheral T-cell lymphomas.
    Mod Pathol 2016 Nov 29;29(11):1306-1312. Epub 2016 Jul 29.
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
    Cyclin D1 is an important regulator of the cell cycle and overexpression of this protein by immunohistochemistry is characteristically seen in mantle cell lymphoma and other B-cell neoplasms. However, little is known about the expression of this protein in T-cell lymphomas. Cyclin-dependent kinase pathway inhibitors are in development, therefore identifying cyclin D1-positive T-cell lymphomas may provide a therapeutic target in a disease where novel treatments are urgently needed. Read More

    Rare association of cystic squamous cell carcinoma and small lymphocytic B cell lymphoma: successful surgical approach.
    Wien Med Wochenschr 2016 Sep 8. Epub 2016 Sep 8.
    "Onkoderma"-Policlinic for Dermatology and Dermatologic Surgery, General Skobelev 26 blvd., Sofia, Bulgaria.
    Non-melanoma skin cancer is the most common type of cutaneous neoplasm worldwide. While basal cell carcinoma is the most common tumor, squamous cell carcinoma (SCC) causes higher morbidity and has a risk of metastatic spread, depending on immune status, tumor size, and desmoplastic growth. We reported the case of a 77 year old male patient with retroauricular tumor, which started growing 3 years ago and was excised, buth relapsed three times. Read More

    Cutaneous metastasis of inflammatory breast carcinoma mimicking an erythema annulare centrifugum: a sign of locally recurrent cancer.
    Clin Exp Dermatol 2016 Dec 20;41(8):906-910. Epub 2016 Oct 20.
    Department of Oncology, Hospital Casa de Salud, Valencia, Spain.
    Erythema annulare centrifugum (EAC) is a clinical reaction pattern that includes lupus erythematosus, spongiotic dermatitis (particularly pityriasis rosea), pseudolymphoma and cutaneous B-cell lymphoma. However, it can be the result of cutaneous metastasis by an internal carcinoma. We present the case of a 38-year-old woman with bilateral inflammatory breast cancer following multimodal therapy. Read More

    An Aggressive Primary Cutaneous Follicle Center Lymphoma With c-MYC Translocation and CDKN2A (9p21) Deletion: A Case Report and Review of the Literature.
    Am J Dermatopathol 2016 Oct 18. Epub 2016 Oct 18.
    Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY.
    Diffuse large cell B-cell lymphoma of the skin is most commonly represented by diffuse large cell variants of primary cutaneous follicle center lymphoma and the leg-type lymphoma. In a minority of cases, the infiltrates are an expression of stage 4 disease of established extracutaneous B-cell lymphoma. We describe 1 female patient 85 years of age with an aggressive form of primary cutaneous B-cell lymphoma manifesting in multiple firm erythematous indurated solid nodules 1-2 cm each symmetrically on the face periorbitally and on the upper extremities bilaterally. Read More

    Histopathologic spectrum of hypersensitivity reactions associated with anti-CD52 therapy (alemtuzumab).
    J Cutan Pathol 2016 Nov 9;43(11):989-993. Epub 2016 Sep 9.
    Program in Dermatopathology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
    Background: Alemtuzumab is a humanized monoclonal antibody directed against CD52, a cell surface antigen on B and T lymphocytes, and used to treat B-cell chronic lymphocytic leukemia and cutaneous T-cell lymphoma. Skin rash is a common adverse reaction following treatment with alemtuzumab. However, the clinicopathologic features and immunologic basis for the reaction have not been previously reported. Read More

    Cutaneous B-cell lymphomas: 2016 update on diagnosis, risk-stratification, and management.
    Am J Hematol 2016 Oct;91(10):1052-5
    Division of Hematology/Oncology University of Michigan Cancer Center, 1500 E. Medical Center Drive Room 4310 CC, Ann Arbor, Michigan, 48109-5948.
    Disease Overview: Approximately one-fourth of cutaneous lymphomas are B-cell derived and are generally classified into three distinct subgroups: primary cutaneous follicle center lymphoma (PCFCL), primary cutaneous marginal zone lymphoma (PCMZL), and primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL, LT).

    Diagnosis: Diagnosis and disease classification is based on histologic review and immunohistochemical staining of an appropriate skin biopsy. Pathologic review and an appropriate staging evaluation are necessary to distinguish primary cutaneous B-cell lymphomas from systemic B-cell lymphomas with secondary skin involvement. Read More

    Primary Cutaneous B-Cell Lymphoma - Systemic spread is rare whilst cutaneous relapses and secondary malignancies are frequent.
    Br J Dermatol 2016 Sep 19. Epub 2016 Sep 19.
    University Hospital Birmingham, West Midlands.
    Primary cutaneous B-cell lymphomas (CBCL) are rare lymphomas sub-classified as marginal zone lymphoma (MZL), follicle cell lymphoma (FCC) or primary cutaneous large B-cell lymphoma (PCLBCL) according to the 2005 World Health Organisation - European Organisation for Research and Treatment of Cancer (WHO-EORTC) Classification(1) . The management and prognosis varies between subtypes(2) . This cohort study of CBCL patients from Birmingham Specialist Cutaneous Lymphoma Service reports on demographics, staging, treatment and outcomes of patients. Read More

    Cutaneous Richter Syndrome mimicking a lower limb cellulitis infection - a case report and review of the literature.
    Dermatol Online J 2016 May 15;22(5). Epub 2016 May 15.
    Department of Dermatology and Venereology, Centro Hospitalar São João EPE, Porto, Portugal; Faculty of Medicine, University of Porto, Portugal.
    Richter syndrome (RS) is characterized by the development of a high-grade lymphoma in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Herein, we present the case of an 85-year-old woman with a 3-year history of stable asymptomatic CLL that developed a cutaneous RS. The patient presented with painless inflammation in the left leg and foot that was initially diagnosed as a cellulitis infection. Read More

    Plasmablastic lymphoma: an atypical cutaneous presentation of a rare entity.
    Dermatol Online J 2016 May 15;22(5). Epub 2016 May 15.
    Dermatology Department, Centro Hospitalar do Porto, Porto, Portugal.
    Plasmablastic lymphoma is a very rare B-cell lymphoma typically associated with immunosuppression: It occurs primarily in the oral cavity, although some cases were reported in other organs and tissues.To date, only 10 cases of primary cutaneous plasmablastic lymphoma have been described. Clinically, primary cutaneous plasmablastic lymphoma presents as non-specific cutaneous lesions (purple nodules, erythematous infiltrated plaques). Read More

    Rituximab: Uses in Dermatology.
    Skin Therapy Lett 2016 Sep;21(5):5-7
    Department of Dermatology, The University of Texas Medical Branch, Galveston, TX, USA.
    Rituximab is an anti-CD20 monoclonal antibody with considerable potential in dermatology due to an increase in off-label indications. Chronic graft-versus-host disease and pemphigus vulgaris are two of the most promising indications for off-label use of rituximab. It is a generally safe alternative that should be considered when traditional therapy with corticosteroids or immunosuppressants has failed or caused significant intolerance. Read More

    Angioimmunoblastic T-cell lymphoma with a clonal plasma cell proliferation that underwent immunoglobulin isotype switch in the skin, coinciding with cutaneous disease progression.
    J Cutan Pathol 2016 Dec 4;43(12):1203-1210. Epub 2016 Oct 4.
    Pathology Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
    Plasma cell proliferations in specific cutaneous lesions of angioimmunoblastic T-cell lymphoma(AITL) are very uncommon. Here, we report a case of clonal plasma cell proliferation in skin with heavy-chain-immunoglobulin-isotype-switch after cutaneous disease progression. Histopathologically, initial plaque lesions were suggestive of marginal-zone B-cell-lymphoma. Read More

    Therapeutic Use of Brentuximab Vedotin In Cd30+ Hematologic Malignancies.
    Anticancer Agents Med Chem 2016 Sep 2. Epub 2016 Sep 2.
    Division of Hematology, University Hospital Viale Bracci - 53100 Siena, Italy.
    The CD30 antigen is strongly expressed on neoplastic cells in classical Hodgkin lymphoma (HL), anaplastic large cell lymphoma (ALCL) and other hematologic malignancies (such as DLBCL and cutaneous TCL), while is almost undetectable on healthy tissues, representing an ideal immunotherapeutic target. Since unconjugated anti-CD30 antibody (SGN-30) demonstrated limited clinical activity, researchers' effort aimed to create an antibody-drug conjugate (ADC), leading to discovery of SGN-35 (brentuximab vedotin), in which an anti-CD30 antibody is linked to the antimitotic agent monomethyl auristatin E (MMAE). In the first phase I study in CD30+ hematologic malignancies (the majority of patients with HL) the maximum tolerated dose was fixed at 1. Read More

    X-Ray Psoralen Activated Cancer Therapy (X-PACT).
    PLoS One 2016 1;11(9):e0162078. Epub 2016 Sep 1.
    Department of Medicine, Duke University Medical Center, Durham, North Carolina, United States of America.
    This work investigates X-PACT (X-ray Psoralen Activated Cancer Therapy): a new approach for the treatment of solid cancer. X-PACT utilizes psoralen, a potent anti-cancer therapeutic with current application to proliferative disease and extracorporeal photopheresis (ECP) of cutaneous T Cell Lymphoma. An immunogenic role for light-activated psoralen has been reported, contributing to long-term clinical responses. Read More

    Primary cutaneous plasmablastic lymphoma revealing clinically unsuspected HIV infection.
    An Bras Dermatol 2016 Jul-Aug;91(4):507-9
    Universidade Estadual Paulista "Júlio de Mesquita Filho" (UNESP) - Botucatu (SP), Brazil.
    Plasmablastic lymphoma is a rare subtype of diffuse large B-cell lymphoma more frequently diagnosed in immunosuppressed patients, mainly HIV-infected. Primary cutaneous plasmablastic lymphoma is extremely rare, and in this patient it was the first clinical manifestation of unsuspected HIV-infection. Read More

    Approach to Cutaneous Lymphoid Infiltrates: When to Consider Lymphoma?
    Indian J Dermatol 2016 Jul-Aug;61(4):351-74
    Department of Dermatology and Pathology, University of California, San Francisco, United States of America.
    Cutaneous lymphoid infiltrates (CLIs) are common in routine dermatopathology. However, differentiating a reactive CLI from a malignant lymphocytic infiltrate is often a significant challenge since many inflammatory dermatoses can clinically and/or histopathologically mimic cutaneous lymphomas, coined pseudolymphomas. We conducted a literature review from 1966 to July 1, 2015, at PubMed. Read More

    1 OF 48